APA

Volz N. B., Stintzing S., Zhang W., Yang D., Ning Y., Wakatsuki T., El-Khoueiry R. E., Li J. E., Kardosh A., Loupakis F., Cremolini C., Falcone A., Scherer S. J. & Lenz H. (20150928). Genes involved in pericyte-driven tumor maturation predict treatment benefit of first-line FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer. : The pharmacogenomics journal.

Chicago

Volz N B, Stintzing S, Zhang W, Yang D, Ning Y, Wakatsuki T, El-Khoueiry R E, Li J E, Kardosh A, Loupakis F, Cremolini C, Falcone A, Scherer S J and Lenz H-J. 20150928. Genes involved in pericyte-driven tumor maturation predict treatment benefit of first-line FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer. : The pharmacogenomics journal.

Harvard

Volz N. B., Stintzing S., Zhang W., Yang D., Ning Y., Wakatsuki T., El-Khoueiry R. E., Li J. E., Kardosh A., Loupakis F., Cremolini C., Falcone A., Scherer S. J. and Lenz H. (20150928). Genes involved in pericyte-driven tumor maturation predict treatment benefit of first-line FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer. : The pharmacogenomics journal.

MLA

Volz N B, Stintzing S, Zhang W, Yang D, Ning Y, Wakatsuki T, El-Khoueiry R E, Li J E, Kardosh A, Loupakis F, Cremolini C, Falcone A, Scherer S J and Lenz H-J. Genes involved in pericyte-driven tumor maturation predict treatment benefit of first-line FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer. : The pharmacogenomics journal. 20150928.